Newmain Human Dermatech Funds Cuts MSBIO Stake to 8.22%
Newmain Human Dermatech Funds reduced its stake in MSBIO to 8.22%.
Related stories
West Pharma executive says GLP-1 drugs helped drive growth in India and China
A West Pharma executive said GLP-1 drugs helped drive growth in India and China, according to a conference call.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Q3 Net Profit Rises 6.98% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
OMV Petrom Publishes Q3 2026 Results Presentation Transcript
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Reports Q3 Revenue Up 14.6% Year Over Year
Luxshare Precision said third-quarter revenue rose 14.6% year over year.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Says Q3 Revenue Rose 14.6% YoY
Luxshare Precision said third-quarter revenue increased 14.6% year over year.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Says Q3 Net Profit Rose 7% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC